Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

NCT05912075 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT05912075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05912075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 1
Overall status
Recruiting
Start date
December 19, 2023
Completion date
January 31, 2029
Enrollment
78 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally-advanced rectal cancer